HR 6321 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Lung Cancer Medicare Access to Precise Testing Act
To amend title XVIII of the Social Security Act to require coverage of lung cancer biomarker testing under the Medicare program.
Summary
This bill would require Medicare to cover lung cancer biomarker testing, which identifies specific genetic or molecular characteristics of a patient's cancer to guide treatment decisions. Medicare would pay 100 percent of the reasonable charges for such testing with no cost-sharing for beneficiaries. The coverage would apply to tests performed on or after January 1, 2027, for individuals diagnosed with lung cancer. The testing is performed on tissue, blood, or bodily fluid samples to identify genes, proteins, or other molecules relevant to treatment selection.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
3 cosponsors
Money behind the sponsor
Top reported contributors to Josh Gottheimer’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- BLACKSTONE $116,700
- APOLLO GLOBAL MANAGEMENT $71,500
- KKR & CO INC. $50,600
- CENTERVIEW PARTNERS $25,000
- FORTRESS INVESTMENT GROUP $23,200
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Josh Gottheimer → · Outside spending →
Actions (2)
- Nov 28, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
- Nov 28, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
November 28, 2025
Mr. Gottheimer (for himself and Mrs. Kiggans of Virginia) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
A BILL
To amend title XVIII of the Social Security Act to require coverage of lung cancer biomarker testing under the Medicare program.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Lung Cancer Medicare Access to Precise Testing Act”.
SEC. 2. REQUIRING COVERAGE OF LUNG CANCER BIOMARKER TESTING UNDER MEDICARE.
(a) Coverage.—Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended—
(1) in subsection (s)(2)—
(A) in subparagraph (JJ), by adding “and” at the end; and
(B) by adding at the end the following new subparagraph: “(KK) lung cancer biomarker testing (as defined in subsection (nnn));”; and
(2) by adding at the end the following new subsection: “(nnn) Lung Cancer Biomarker Testing.—The term ‘lung cancer biomarker testing’ means a test furnished on or after January 1, 2027, to an individual diagnosed with lung cancer for the identification of 1 or more specific biomarkers (such as genes, proteins, or other molecules) based on the analysis of such individual’s tissue, blood, or bodily fluids.”.
(b) Payment.—Section 1833(a)(1) of the Social Security Act (42 U.S.C. 1395y(a)(1)) is amended—
(1) by striking “and (HH)” and inserting “(HH)”; and
(2) by inserting “, and (II) with respect to lung cancer biomarker testing (as defined in section 1861(nnn)), the amount paid shall be 100 percent of the reasonable charges for such testing” before the semicolon at the end. <all>
Comments